Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy. The potential significance of these data for the management of patients with BRCA1-related and BRCA2-related breast cancer is...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Nicholas C, Tutt, Andrew NJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053124/
https://www.ncbi.nlm.nih.gov/pubmed/23146216
http://dx.doi.org/10.1186/bcr3332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053124/
https://www.ncbi.nlm.nih.gov/pubmed/23146216
http://dx.doi.org/10.1186/bcr3332

Ejemplares similares